About Bright Minds Biosciences Inc.
https://brightmindsbio.comBright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
CEO
Ian McDonald
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-14 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 24
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:1.15M
Value:$103.36M
CORMORANT ASSET MANAGEMENT, LP
Shares:1.06M
Value:$95.57M
VIVO CAPITAL, LLC
Shares:501.62K
Value:$45.26M
Summary
Showing Top 3 of 65
About Bright Minds Biosciences Inc.
https://brightmindsbio.comBright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $4.05M ▲ | $-2.93M ▲ | 0% | $-0.41 ▲ | $-486.56K ▲ |
| Q3-2025 | $0 | $3.3M ▼ | $-5.24M ▼ | 0% | $-0.74 ▼ | $-3.28M ▲ |
| Q2-2025 | $0 | $3.35M ▲ | $-2.95M ▼ | 0% | $-0.66 ▼ | $-3.33M ▼ |
| Q1-2025 | $0 | $1.62M ▲ | $49.61K ▲ | 0% | $0.01 ▲ | $-1.6M ▼ |
| Q4-2024 | $0 | $764.46K | $-749.32K | 0% | $-0.17 | $-772.29K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $82.91M ▲ | $84.42M ▲ | $2.38M ▲ | $58.91M ▲ |
| Q3-2025 | $51.39M ▼ | $52.5M ▼ | $667.83K ▼ | $51.83M ▼ |
| Q2-2025 | $55.68M ▼ | $56.47M ▼ | $726.81K ▲ | $55.74M ▼ |
| Q1-2025 | $57.9M ▲ | $58.4M ▲ | $571.59K ▲ | $57.83M ▲ |
| Q4-2024 | $5.72M | $6.1M | $568.26K | $5.54M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-4.09M ▲ | $-910.43K ▲ | $0 | $23.92M ▲ | $21.79M ▲ | $-910.43K ▲ |
| Q3-2025 | $-5.24M ▼ | $-3.5M ▼ | $0 | $-16.87K ▼ | $-4.29M ▼ | $-3.5M ▼ |
| Q2-2025 | $-2.95M ▼ | $-2.43M ▼ | $0 | $225.38K ▼ | $-2.22M ▼ | $-2.43M ▼ |
| Q1-2025 | $49.61K ▲ | $-1.49M ▼ | $0 | $52.04M ▲ | $52.18M ▲ | $-1.49M ▼ |
| Q4-2024 | $-773.44K | $-463.17K | $0 | $-23.56K | $-470.15K | $-463.17K |
CEO
Ian McDonald
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-14 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 24
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:1.15M
Value:$103.36M
CORMORANT ASSET MANAGEMENT, LP
Shares:1.06M
Value:$95.57M
VIVO CAPITAL, LLC
Shares:501.62K
Value:$45.26M
Summary
Showing Top 3 of 65